Brokerages Expect CRISPR Therapeutics AG (NASDAQ:CRSP) Will Post Quarterly Sales of $4.23 Million

Wall Street analysts forecast that CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) will report sales of $4.23 million for the current fiscal quarter, Zacks reports. Six analysts have made estimates for CRISPR Therapeutics’ earnings. The lowest sales estimate is $200,000.00 and the highest is $14.80 million. CRISPR Therapeutics posted sales of $900.70 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 99.5%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that CRISPR Therapeutics will report full year sales of $187.03 million for the current year, with estimates ranging from $1.00 million to $940.00 million. For the next fiscal year, analysts forecast that the business will post sales of $231.76 million, with estimates ranging from $3.37 million to $727.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow CRISPR Therapeutics.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.94) by ($0.38). The firm had revenue of $0.94 million during the quarter, compared to the consensus estimate of $2.45 million. CRISPR Therapeutics had a net margin of 34.04% and a return on equity of 12.77%. CRISPR Therapeutics’s quarterly revenue was up 74.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.51) EPS.

CRSP has been the subject of a number of analyst reports. Truist Financial reiterated a “buy” rating and issued a $220.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, February 16th. Stifel Nicolaus reduced their price objective on shares of CRISPR Therapeutics to $64.00 in a research note on Wednesday, February 16th. They noted that the move was a valuation call. SVB Leerink dropped their target price on shares of CRISPR Therapeutics from $126.00 to $120.00 and set an “outperform” rating on the stock in a report on Wednesday, February 16th. Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $171.00 to $168.00 in a report on Tuesday, May 10th. Finally, Barclays dropped their target price on shares of CRISPR Therapeutics from $107.00 to $99.00 in a report on Tuesday, May 10th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics has an average rating of “Hold” and an average target price of $121.60.

CRISPR Therapeutics stock opened at $56.34 on Friday. The firm has a 50-day moving average of $58.69 and a 200-day moving average of $66.48. The company has a market cap of $4.36 billion, a price-to-earnings ratio of 15.61 and a beta of 2.05. CRISPR Therapeutics has a one year low of $42.51 and a one year high of $169.76.

Several hedge funds have recently made changes to their positions in the stock. Capital International Sarl lifted its stake in shares of CRISPR Therapeutics by 20.0% during the 1st quarter. Capital International Sarl now owns 24,189 shares of the company’s stock valued at $1,518,000 after buying an additional 4,027 shares in the last quarter. Capital International Investors lifted its stake in shares of CRISPR Therapeutics by 0.3% during the 1st quarter. Capital International Investors now owns 3,602,152 shares of the company’s stock valued at $226,107,000 after buying an additional 10,992 shares in the last quarter. Virtu Financial LLC lifted its stake in shares of CRISPR Therapeutics by 106.0% during the 1st quarter. Virtu Financial LLC now owns 22,401 shares of the company’s stock valued at $1,406,000 after buying an additional 11,525 shares in the last quarter. Mirabella Financial Services LLP purchased a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $220,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $5,176,000. Institutional investors own 56.12% of the company’s stock.

About CRISPR Therapeutics (Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Recommended Stories